Charles Schwab Investment Management Inc Jounce Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.99 $10,623 - $33,032	-16,599 Reduced 6.84%	226,160 $251,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $316 - $570	-116 Reduced 0.05%	242,759 $569,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $96,356 - $263,947	-34,413 Reduced 12.41%	242,875 $736,000
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $802,996 - $1.14 Million	133,610 Added 92.99%	277,288 $1.88 Million
Q4 2021 Feb 11, 2022	BUY	$7.11 - $9.64 $661 - $896	93 Added 0.06%	143,678 $1.2 Million
Q3 2021 Nov 16, 2021	SELL	$5.04 - $8.73 $577,115 - $999,646	-114,507 Reduced 44.37%	143,585 $1.07 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $382,094 - $619,015	58,069 Added 29.03%	258,092 $1.76 Million
Q1 2021 May 17, 2021	SELL	$6.73 - $13.87 $366,785 - $755,915	-54,500 Reduced 21.41%	200,023 $2.06 Million
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $349,464 - $566,714	-54,861 Reduced 17.73%	254,523 $1.78 Million
Q3 2020 Nov 13, 2020	BUY	$4.58 - $10.95 $114,797 - $274,461	25,065 Added 8.82%	309,384 $2.53 Million
Q2 2020 Aug 14, 2020	BUY	$4.17 - $7.58 $213,645 - $388,353	51,234 Added 21.98%	284,319 $1.96 Million
Q1 2020 May 15, 2020	BUY	$2.91 - $8.7 $105,769 - $316,218	36,347 Added 18.47%	233,085 $1.11 Million
Q4 2019 Feb 07, 2020	BUY	$2.81 - $9.21 $269,903 - $884,629	96,051 Added 95.4%	196,738 $1.72 Million
Q3 2019 Nov 08, 2019	BUY	$3.33 - $4.93 $15,767 - $23,343	4,735 Added 4.93%	100,687 $336,000
Q2 2019 Aug 09, 2019	BUY	$4.3 - $6.73 $5,198 - $8,136	1,209 Added 1.28%	95,952 $475,000
Q1 2019 May 14, 2019	BUY	$3.43 - $6.87 $35,414 - $70,932	10,325 Added 12.23%	94,743 $588,000
Q4 2018 Feb 14, 2019	BUY	$2.69 - $6.71 $22,929 - $57,196	8,524 Added 11.23%	84,418 $285,000
Q3 2018 Nov 13, 2018	BUY	$6.5 - $8.37 $181,629 - $233,882	27,943 Added 58.27%	75,894 $494,000
Q2 2018 Aug 08, 2018	BUY	$7.27 - $21.88 $58,908 - $177,293	8,103 Added 20.33%	47,951 $368,000
Q1 2018 May 07, 2018	SELL	$13.4 - $28.4 $35,925 - $76,140	-2,681 Reduced 6.3%	39,848 $891,000
Q4 2017 Jan 17, 2018	BUY	$12.52 - $17.82 $13,671 - $19,459	1,092 Added 2.64%	42,529 $543,000
Q3 2017 Nov 13, 2017	BUY	$11.17 - $16.99 $462,851 - $704,014	41,437	41,437 $646,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account